Treatment of 5 critically ill patients with COVID-19 with convalescent plasma
Coronavirus disease 2019 ( COVID-19 ) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.
The objective of a study was to determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) infection.
Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome ( ARDS ) who met the following criteria were analysed: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 less than 300; and mechanical ventilation.
All 5 were treated with convalescent plasma transfusion.
The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020.
Clinical outcomes were compared before and after convalescent plasma transfusion.
Patients received transfusion with convalescent plasma with a SARS-CoV-2–specific antibody ( IgG ) binding titer greater than 1:1000 ( end point dilution titer, by enzyme-linked immunosorbent assay [ ELISA ] ) and a neutralization titer greater than 40 ( end point dilution titer ) that had been obtained from 5 patients who recovered from COVID-19.
Convalescent plasma was administered between 10 and 22 days after admission.
All 5 patients ( age range, 36-65 years; 2 women ) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and Methylprednisolone.
Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days ( range, 172-276 before and 284-366 after ).
Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2–specific ELISA and neutralizing antibody titers increased following the transfusion ( range, 40-60 before and 80-320 on day 7 ).
ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment.
Of the 5 patients, 3 have been discharged from the hospital ( length of stay: 53, 51, and 55 days ), and 2 are in stable condition at 37 days after transfusion.
In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in clinical status.
The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials. ( Xagena )
Source: JAMA, 2020
Real-world ACS population: Ticagrelor doesn’t lessen risks of myocardial infarction or death and may increase bleeding relative to Clopidogrel
Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice of antiplatelet influences...
Changes in the lung microbiome may help predict how well critically ill patients will respond to care. Specifically, patients with higher...
Diabetic patients with COVID-19, characteristics and outcome: a two-centre, retrospective, case control study
Since December 2019, a pneumonia caused by SARS-CoV-2 which was later named as COVID-19 emerged and many people lost...
SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...
Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...
ESC 2019 - ENTRUST-AF PCI trial: Edoxaban dual therapy noninferior to triple therapy in atrial fibrillation post-stenting
Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in...
FDA has approved treatment for patients with endometrial carcinoma: Lenvima in combination with Keytruda
The FDA ( U.S. Food and Drug Administration ) has announced Project Orbis, an initiative of the FDA Oncology Center...
A study has evaluated the efficacy and tolerability of intravenous Lacosamide ( LCM-iv ) under routine conditions in daily clinical...
Kawasaki disease: high-dose Aspirin is associated with anemia and does not confer benefit to disease outcomes
Kawasaki disease ( KD ) is also known as multiple mucocutaneous lymph node syndrome of systemic vasculitis and is a...